logo BDSP

Base documentaire

  1. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.

    Article - En anglais


    Tamoxifen commonly is used as adjuvant therapy for all stages of breast carcinoma.

    However, several studies have suggested an association between the use of tamoxifen in breast carcinoma patients and the subsequent development of endometrial carcinoma.

    The objective of this study was to determine the relation between long term tamoxifen usage and the risk of endometrial carcinoma in patients with breast carcinoma and to determine whether the increase in the cumulative incidence of endometrial carcinoma observed in previous studies is a true increase.


    Eight hundred and twenty-five patients with primary breast carcinoma who underwent annual gynecologic examination and cancer screening were reviewed.

    None of the patients had undergone hysterectomy or received any prior estrogen replacement therapy.

    These patients underwent a pelvic examination and cytologic and/or histologic screening of the cervix and endometrium every year even if they had no gynecologic symptoms.

    The dose of tamoxifen, length of tamoxifen treatment, and potential confounding variables were recorded.

    The relative risk of subsequent endometrial carcinoma in patients with primary breast carcinoma was analyzed by the Cox proportional hazards model.


    Thirteen of the 825 patients developed a subsequent endometrial carcinoma.

    The cumulative incidence of endometrial carcinoma was 1.58%. (...)

    Mots-clés Pascal : Carcinome, Glande mammaire, Epidémiologie, Tamoxifène, Antioestrogène, Antihormone, Anticancéreux, Chimiothérapie, Traitement, Second cancer, Endomètre, Facteur risque, Complication, Toxicité, Carcinogenèse, Japon, Asie, Homme, Composé non stéroïde, Tumeur maligne, Glande mammaire pathologie, Utérus pathologie, Appareil génital femelle pathologie

    Mots-clés Pascal anglais : Carcinoma, Mammary gland, Epidemiology, Tamoxifene, Antiestrogen, Antihormone, Antineoplastic agent, Chemotherapy, Treatment, Second cancer, Endometrium, Risk factor, Complication, Toxicity, Carcinogenesis, Japan, Asia, Human, Non steroid compound, Malignant tumor, Mammary gland diseases, Uterine diseases, Female genital diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0234793

    Code Inist : 002B02U10. Création : 11/09/1998.